V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214535 | 20080807 | 1.78 | 80.5 | Disease modification (D) | 2018-10-21 | 2018-10-22 | LANREOTIDE | 02 | N | LANREOTIDE | 100537302 |
| 20214536 | 20080808 | 1.65 | 81.9 | Curative (C) | 2019-10-13 | 2019-11-01 | IMATINIB | N | N | IMATINIB | 101613306 |
| 20214537 | 20080809 | 1.81 | 56.4 | null | 2017-09-12 | 2017-09-15 | HCX (Cape + Cisp + Tras) - Load | 02 | N | LANREOTIDE | 100487088 |
| 20214538 | 20080810 | 1.67 | 66.8 | Curative (C) | 2016-04-02 | 2016-04-17 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100997126 |
| 20214539 | 20080811 | 1.72 | 0 | Palliative (P) | 2017-12-08 | 2017-12-13 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 100615855 |
| 20214540 | 20080812 | 1.65 | 90 | null | 2016-10-29 | 2016-11-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100605977 |
| 20214542 | 20080813 | 1.8 | 98.1 | Palliative (P) | 2018-01-07 | 2018-02-04 | Imatinib 400mg | 02 | N | IMATINIB | 101318439 |
| 20214543 | 20080814 | 1.57 | 74 | Adjuvant (A) | 2020-01-05 | 2020-01-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | IMATINIB | 100411732 |
| 20214544 | 20080815 | 1.73 | 74.9 | Palliative (P) | 2017-02-12 | 2017-02-23 | Trial Unspecified | 1 | N | TRIAL | 101807236 |
| 20214545 | 20080816 | 1.65 | 54.5 | Palliative (P) | 2020-01-05 | 2020-01-18 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100908679 |
| 20214546 | 20080817 | 1.66 | 116.3 | Curative (C) | 2016-09-11 | 2016-09-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100200134 |
| 20214547 | 20080818 | 1.82 | 53 | Curative (C) | 2016-12-27 | 2017-01-09 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100117717 |
| 20214548 | 20080819 | 1.6 | 78.5 | Curative (C) | 2017-04-24 | 2017-05-06 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100269889 |
| 20214549 | 20080820 | 1.67 | 66.6 | null | 2020-01-21 | 2020-03-02 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101193584 |
| 20214550 | 20080821 | 1.78 | 73.7 | Palliative (P) | 2017-08-07 | 2017-08-07 | Trial Unspecified | 1 | N | TRIAL | 100804336 |
| 20214551 | 20080822 | 1.54 | 103.35 | null | 2019-07-31 | 2019-08-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101676786 |
| 20214552 | 20080823 | 1.69 | 59 | Palliative (P) | 2018-05-27 | 2018-06-03 | Trial Unspecified | 01 | N | TRIAL | 101170190 |
| 20214554 | 20080824 | 1.68 | 56.7 | Palliative (P) | 2019-03-27 | 2019-04-04 | Trial Unspecified | Y | N | TRIAL | 100262802 |
| 20214555 | 20080825 | 1.73 | 65.3 | Curative (C) | 2016-07-15 | 2016-08-12 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100661353 |
| 20214556 | 20080826 | 1.65 | 48.5 | Palliative (P) | 2019-02-13 | 2019-02-19 | Trial Unspecified | Y | N | TRIAL | 101674866 |
| 20214557 | 20080827 | 1.56 | 79.2 | Palliative (P) | 2017-05-08 | 2017-05-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100518855 |
| 20214559 | 20080828 | 1.8 | 68.8 | Curative (C) | 2018-10-28 | 2018-11-15 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101653533 |
| 20214560 | 20080829 | 1.77 | 85 | Palliative (P) | 2018-05-15 | 2018-05-17 | Trial Unspecified | 01 | N | TRIAL | 100455286 |
| 20214561 | 20080830 | null | 61.7 | null | null | 2017-10-03 | LANREOTIDE | 02 | N | LANREOTIDE | 100095549 |
| 20214562 | 20080831 | 1.6 | 50 | Palliative (P) | 2017-04-12 | 2017-04-27 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101745583 |
| 20214564 | 20080832 | 1.75 | 80.1 | Curative (C) | 2017-01-10 | 2017-01-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101512155 |
| 20214565 | 20080833 | null | null | Disease modification (D) | 2017-05-31 | 2017-06-04 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | IMATINIB | 101863214 |
| 20214566 | 20080834 | 1.73 | 65.4 | Palliative (P) | 2016-05-20 | 2016-05-27 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101796512 |
| 20214567 | 20080835 | 1.86 | 75 | Curative (C) | 2020-11-11 | 2020-12-16 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101793255 |
| 20214568 | 20080836 | 1.6 | 65.04 | Curative (C) | 2017-09-21 | 2017-10-11 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101573049 |
| 20214570 | 20080837 | 1.68 | 81.1 | Palliative (P) | 2016-05-18 | 2016-06-04 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100236251 |
| 20214573 | 20080838 | 1.69 | 80 | Palliative (P) | 2019-04-21 | 2019-05-06 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101335428 |
| 20214574 | 20080839 | 1.81 | 75.45 | Palliative (P) | 2018-12-07 | 2018-12-07 | Cape+Cisplatin+Trastuzumab Load | 02 | N | LANREOTIDE | 100412389 |
| 20214575 | 20080840 | 0 | 87 | Palliative (P) | 2019-04-27 | 2019-05-01 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101812671 |
| 20214576 | 20080841 | 1.74 | 85.6 | Neo-adjuvant (N) | 2016-05-17 | 2016-06-08 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101854345 |
| 20214577 | 20080842 | 1.77 | 80.8 | Palliative (P) | 2016-11-26 | 2016-12-10 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100095463 |
| 20214578 | 20080843 | 1.7 | 66 | null | 2018-04-15 | 2018-05-06 | Fluorouracil+Mitomycin+RT (Bladder) | N | N | FLUOROURACIL + MITOMYCIN + RT | 100931639 |
| 20214579 | 20080844 | 1.55 | 65.4 | Palliative (P) | 2018-02-21 | 2018-03-30 | Cetuximab + FLUOROURACIL + FOLINIC ACID + IRINOTECAN | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100308850 |
| 20214581 | 20080845 | 1.63 | 110 | null | 2017-05-02 | 2017-05-07 | LANREOTIDE | 02 | null | LANREOTIDE | 101536633 |
| 20214582 | 20080846 | 1.82 | 73.2 | Curative (C) | 2019-02-25 | 2019-03-11 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101265402 |
| 20214583 | 20080847 | 0 | 64 | Palliative (P) | 2018-10-15 | 2018-11-04 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 101551641 |
| 20214584 | 20080848 | 1.57 | 92 | Palliative (P) | 2019-02-20 | 2019-02-20 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100907580 |
| 20214585 | 20080849 | 1.74 | 73.1 | Palliative (P) | 2019-04-07 | 2019-04-12 | CAPECITABINE + CISPLATIN + Trastuzumab | null | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100678103 |
| 20214586 | 20080850 | 1.58 | 0 | Curative (C) | 2018-09-08 | 2018-10-12 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101070019 |
| 20214587 | 20080851 | 1.71 | 82 | Curative (C) | 2016-10-15 | 2016-10-23 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101666972 |
| 20214588 | 20080852 | 1.54 | 0 | Palliative (P) | 2018-05-04 | 2018-05-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100981555 |
| 20214589 | 20080853 | 1.67 | 71.5 | Palliative (P) | 2017-09-07 | 2017-09-09 | IMATINIB | 02 | N | IMATINIB | 100695428 |
| 20214591 | 20080854 | 1.52 | 120 | Adjuvant (A) | 2018-04-04 | 2018-04-05 | IMATINIB | 02 | N | IMATINIB | 100623323 |
| 20214592 | 20080855 | 1.57 | 80.3 | Curative (C) | 2018-01-31 | 2018-04-01 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | null | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100512591 |
| 20214593 | 20080856 | 1.6 | 60.7 | Palliative (P) | 2019-02-02 | 2019-02-24 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101625161 |